CHINARES PHARMA (03320) announced that on December 15, 2025, its non-wholly owned subsidiary, China Resources Pharmaceutical Commercial Group Co., Ltd., successfully issued the first tranche of its 2025 medium-term notes in China. The issuance amounted to RMB3 billion with a three-year tenor (renewable at maturity) and an annual coupon rate of 2.19%. The proceeds from the issuance will be used to repay interest-bearing debts of China Resources Pharmaceutical Commercial or its subsidiaries.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.